Fulcrum Therapeutics Inc. (FULC) Tops Q2 EPS by 128c
Tweet
Share
E-mail
Get Alerts FULC Hot Sheet
Join SI Premium – FREE
Fulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q2 EPS of $0.87, $1.28 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $80 million versus the consensus estimate of $1.78 million.
For earnings history and earnings-related data on Fulcrum Therapeutics Inc. (FULC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evogene (EVGN) Tops Q2 EPS by 15c
- H.C. Wainwright Reiterates Buy Rating on Hive Digital Technologies (HIVE)
- uCloudlink Group Inc. (UCL) Misses Q2 EPS by 1c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
